Compound guide · Metabolic & GLP-1
Retatrutide: what it is, its legal status and the evidence
The triple agonist sold off-label for body recomposition — unapproved for any use.
What the evidence shows
The strongest phase-2 human data of any compound on this site, for weight loss specifically; body-recomposition-in-athletes claims go beyond the trial evidence.
Read the full review: Is Retatrutide FDA Approved? TRIUMPH Results and the Approval Timeline
Legal and FDA status
An investigational drug with no approved product anywhere in the world, and no entry on any FDA compounding table — so there is no compounding route and no pending one. Its Phase 3 trials reported in 2026 and Lilly plans to seek FDA approval in early 2027, but until a label exists, everything sold under this name is an unapproved drug.
Anti-doping status
Retatrutide is a next-generation GLP-1/GIP/glucagon triple agonist that is still unapproved, so — unlike the approved GLP-1 drugs — it falls under S0 and is prohibited at all times, exactly like other research-only peptides.
Read next: every Retatrutide guide
What the evidence says
Dosage and how it's taken
Side effects and safety
How it compares
Cost and buying
Is there a legal way to get it?
Not lawful to compound, so we list no sellers of Retatrutide. A prescription option we compare instead:
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.